other
Eli Lilly's weight-loss drug containing tirzepatide, a dual GIP/GLP-1 receptor agonist used for chronic obesity management.
No evidence-backed relationships are recorded.
Japan's obesity society warned cosmetic GLP-1 users of side-effect risks, as 35 of about 950 Mounjaro side-effect reports involved dieting or cosmetic use. The health ministry separately said the drugs should not be used casually as weight-loss pills.
Reality
One personal injury firm has filed more than 90 New Jersey suits claiming Novo Nordisk's Ozempic and Wegovy caused sudden vision loss. Denmark has awarded about $55,600 a patient for the same injury, the only price on record, while studies of whether the drugs cause it still disagree.
Reality
Prescribing has outrun the approval label for US children aged 8 to 11 with obesity. The trial behind the benefit claim followed them for 68 weeks. Those 68 weeks are the entire developmental record so far.
Reality
The FDA is investigating whether GLP-1 drugs cause sudden vision loss, and the New Jersey filings number in the dozens. The market those drugs sell into is projected at $92 billion this year.
Reality
More than 90 New Jersey suits and dozens more against Novo Nordisk and Eli Lilly turn on a warning the FDA has not written while four other jurisdictions added theirs. Denmark's payouts are the only money that has moved so far.
Reality
A 2026 JAMA Surgery analysis shows surgical obesity care losing a third of its volume in two years. The spend has not vanished; it has moved to the pharmacy benefit, where coverage decides who gets treated.
Reality
A Cambridge mouse study locates the GIP paradox in anatomy: agonists act through the brainstem, antagonists release a hypothalamic brake. Combination design becomes a targeting question.
Reality